This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Can CYTK Clinch a Potential FDA Nod for Its Cardiovascular Drug?
by Zacks Equity Research
Cytokinetics' aficamten shows superiority over metoprolol in late-stage oHCM trial, boosting investor confidence despite FDA delay.
BMYPositive Net Change BAYRYPositive Net Change CYTKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
ALNY's portfolio of rare disease and cardiovascular drugs is boosting revenues and reducing reliance on Amvuttra.
ALNYPositive Net Change NVSPositive Net Change PFEPositive Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?
by Kanishka Das
Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.
RHHBYNegative Net Change MRKNegative Net Change CORTPositive Net Change
medical
Is IPF the Next Big Market Opportunity for United Therapeutics?
by Sundeep Ganoria
UTHR reports strong TETON-2 results for Tyvaso in IPF, showing lung function gains and eyeing a major new market.
UTHRNegative Net Change INSMNegative Net Change LQDAPositive Net Change
biotechs medical
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
by Zacks Equity Research
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
DGXPositive Net Change TMOPositive Net Change QGENPositive Net Change
medical
ISRG Expands SP Indications: A Game Changer in Colorectal Surgery?
by Indrajit Bandyopadhyay
Intuitive Surgical's SP platform secures new colorectal clearances, with 88% growth in procedures and rising global adoption momentum.
JNJNegative Net Change MDTNegative Net Change ISRGPositive Net Change
medical medical-devices
Is Veeva's Vault CRM Emerging as the Standard for Top Biopharma?
by Zacks Equity Research
VEEV's Vault CRM is gaining traction with top biopharma firms like Merck, Gilead, and BMS, signaling its rise as the industry's commercial standard.
CRMPositive Net Change VEEVPositive Net Change IQVNo Net Change
medical medical-devices
Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline
by Zacks Equity Research
Kymera advances its protein degradation pipeline with new Sanofi and Gilead deals, milestone payouts, and promising trial updates.
SNYNegative Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
BD & Henry Ford Health Tie-Up to Enhance Community Pharmacy Experience
by Zacks Equity Research
BDX partners with Henry Ford Health to deploy BD Rowa Vmax robots, aiming to streamline 24/7 pharmacy access in Michigan.
BDXNegative Net Change BAXNegative Net Change MCKNegative Net Change OMCLNegative Net Change
medical medical-devices
Hologic Bets on Endomagnetics to Fuel Interventional Breast Momentum
by Moumi Mondal
HOLX's Interventional Breast business hits $100M as Endomag products boost recurring revenues and margins.
BSXPositive Net Change SYKNegative Net Change HOLXNegative Net Change
medical medical-devices
New Strong Sell Stocks for October 1st
by Zacks Equity Research
AGL, PLAY and CCRN have been added to the Zacks Rank #5 (Strong Sell) List on October 1, 2025.
AGLNegative Net Change CCRNPositive Net Change PLAYNegative Net Change
business-services medical restaurants
Unlocking Cures: How AI is Reshaping Cancer Research & Healthcare ETFs?
by Aparajita Dutta
AI's growing role in cancer research, and a new federal push for pediatric oncology, are powering gains in key healthcare ETFs.
VHTPositive Net Change XBIPositive Net Change IXJNo Net Change
medical
Can NVO Maintain Obesity Leadership With Next-Generation Candidates?
by Ahan Chakraborty
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Krystal Biotech's Heavy Reliance on Vyjuvek: Growth Driver or Risk Factor?
by Zacks Equity Research
KRYS gains momentum with Vyjuvek's expanded FDA label and global approvals, while advancing a pipeline led by oncology candidate KB707.
BMYPositive Net Change MRKNegative Net Change ABEONegative Net Change KRYSPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
OptimizeRx Bets on AI and Workflow Integration - Will This Pay Off?
by Indrajit Bandyopadhyay
OPRX posts 55% revenue growth and raises outlook as AI-driven workflow integration fuels leverage and pharma adoption.
OMCLNegative Net Change OPRXPositive Net Change TDOCNegative Net Change
medical medical-devices
PacBio Enters Carrier Screening Market With PureTarget Expansion
by Zacks Equity Research
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
TMOPositive Net Change ILMNPositive Net Change QGENPositive Net Change PACBPositive Net Change
medical medical-devices
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
by Zacks Equity Research
QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.
TMOPositive Net Change HOLXNegative Net Change QGENPositive Net Change QDELPositive Net Change
medical medical-devices
Here's How Alvotech is Expanding its Portfolio Beyond Immunology
by Sundeep Ganoria
ALVO accelerates growth with soaring revenues and new biosimilars in ophthalmology, oncology and neurology via global alliances.
RDYNegative Net Change TEVAPositive Net Change ALVONegative Net Change
biotechs medical
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
by Zacks Equity Research
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
DGXPositive Net Change QGENPositive Net Change EXASPositive Net Change GHPositive Net Change
medical medical-devices
New Strong Buy Stocks for September 30th
by Zacks Equity Research
UGP, PDS, FUTU, PAHC and PGY have been added to the Zacks Rank #1 (Strong Buy) List on September 30, 2025.
PDSPositive Net Change UGPPositive Net Change PAHCPositive Net Change FUTUPositive Net Change PGYPositive Net Change
business-services finance medical oil-energy
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
by Zacks Equity Research
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
HALOPositive Net Change ABBVNegative Net Change ANIPNegative Net Change ARGXNegative Net Change
biotechs medical pharmaceuticals
Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
by Kanishka Das
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
SNYNegative Net Change RDYNegative Net Change LLYPositive Net Change RIGLNegative Net Change
medical
IDEXX Laboratories Stock Rallies 52.9% YTD: What's Behind the Drive?
by Zacks Equity Research
IDXX soars 52.9% YTD, fueled by strong CAG Diagnostics growth, global expansion and rising demand for software solutions.
BSXPositive Net Change CAHPositive Net Change MASINegative Net Change IDXXPositive Net Change
medical medical-devices
FDA Approves Label Extension of REGN's Cholesterol Drug Evkeeza
by Zacks Equity Research
Regeneron wins FDA approval to extend Evkeeza use in children as young as one with severe familial hypercholesterolemia.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change RARENegative Net Change
biotechnology biotechs medical pharmaceuticals
Bio-Techne Stock Climbs on Advances in Spatial Biology Solutions
by Zacks Equity Research
TECH shares rise as advances in RNAscope and COMET spotlight new roles in lymphoid malignancy diagnostics.
MASINegative Net Change TECHPositive Net Change PAHCPositive Net Change NVSTPositive Net Change
medical